Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...
March 30, 2026 07:20 ET | Source: Can-Fite BioPharma Ltd.

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a...
March 30, 2026 06:50 ET | Source: Ellomay Capital Ltd

Ellomay Capital to Sell its Indirect Holdings in Dorad Energy Ltd. based on a Dorad Valuation of NIS 4.4 Billion

Tel-Aviv, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable...
March 26, 2026 09:27 ET | Source: Can-Fite BioPharma Ltd.

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs...
March 26, 2026 08:55 ET | Source: Foresight Autonomous Holdings Ltd.

Foresight Announces Fourth Quarter and Full Year 2025 Financial Results

NESS ZIONA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd., (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today...
March 26, 2026 08:36 ET | Source: Formula Systems (1985) Ltd.

Formula Systems Reports Fourth Quarter and Full Year 2025 Financial Results

PRESS RELEASE 2025 Full-year revenues increased by 18.4% year over year, reaching $2.63 billion. Net income attributable to Formula shareholders reached $606.5 million following the completion of...
March 26, 2026 08:30 ET | Source: Pluri Inc.

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple...
March 26, 2026 07:30 ET | Source: BrainsWay

BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
March 26, 2026 07:00 ET | Source: Kamada Ltd.

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual...
March 25, 2026 09:05 ET | Source: Tower Semiconductor

Tower Semiconductor Announces Plans to Expand 300mm Capacity in Japan to Support Strong Customer Demand

Planned expansion supports the TPSCo announced transition while strengthening Tower’s differentiated optical and photonics platforms and enabling growth across these high-value technology offerings ...